Group 1: Company Overview and Performance - The company, Guangdong Yiduoli Biotechnology Co., Ltd., focuses on two main sectors: animal feed and industrial enzyme products [1][2] - In 2024, the company expects to produce 41,533 tons of biological enzyme preparations, with sales reaching 42,383 tons, resulting in a sales rate exceeding 100% [8] - The sales proportion of the top five customers in 2024 is 13.75%, with domestic and international market shares at 67.59% and 32.41% respectively [8] Group 2: Market Expectations and Product Development - The company anticipates stable growth in both domestic and international markets for its industrial enzyme products, which cover various applications including bioenergy and food [2][7] - New product developments include biodegradable enzymes for environmental applications, with R-PET enzyme currently in the conversion stage [6][7] - The company has developed a high-yield strain of calcium propionate to replace traditional chemical synthesis methods, with ongoing optimization of previously developed products [3] Group 3: Risk Management and Financial Health - The company maintains a focus on asset quality, with no current pressure for asset impairment due to proactive management and dynamic assessments [4][5] - A customer credit evaluation system is in place to manage accounts receivable risks, while dynamic inventory management helps mitigate stock depreciation [4] Group 4: Strategic Initiatives and International Expansion - The company is expanding its international presence, with a completed German subsidiary and a planned Brazilian subsidiary to enhance market opportunities [7][9] - The company is committed to enhancing its marketing network and local brand development in overseas markets [7][9] Group 5: Competitive Landscape and Regulatory Environment - The company is positioned to benefit from the "antibiotic-free" policy in the feed industry, with plant extracts gaining market traction despite higher costs compared to antibiotics [6] - The company faces some pressure from market demand fluctuations in the domestic livestock industry, but expects growth as the industry recovers [6]

Core Viewpoint - The biocatalyst industry is experiencing significant growth due to its high efficiency, selectivity, and environmental friendliness, with applications in biotechnology, pharmaceuticals, and food processing [1][4][12]. Biocatalyst Industry Definition and Characteristics - Biocatalysts refer to free or immobilized cells and enzymes that catalyze biological reactions, including various types such as free enzymes, immobilized enzymes, microbial cells, and plant and animal cells [2][4]. Current Development Status of the Biocatalyst Industry - Biocatalysts are highly efficient compared to traditional chemical catalysts, with reaction rates potentially increasing by millions of times when enzymes are involved [4][12]. - In 2024, China's biocatalyst production is projected to reach 195,000 tons, an increase of 12,000 tons from 2023, while demand is expected to rise to 178,000 tons, up by 6,000 tons [5][7]. Biocatalyst Industry Supply Chain - The upstream of the biocatalyst industry includes the supply of fermentation strains, enzyme raw materials, and production equipment, while the midstream focuses on the manufacturing of biocatalysts, and the downstream encompasses applications in pharmaceuticals, food processing, bioenergy, and molecular biology research [7][8]. Competitive Landscape of the Biocatalyst Industry - The biocatalyst industry in China is characterized by intense competition, with multinational companies like Novozymes and DuPont dominating the high-end market, while local firms such as Guangdong Yidoli and Qingdao Blue Biological are expanding their market share through technological innovation [9][10]. Development Trends in the Biocatalyst Industry - Biocatalysts are seen as sustainable alternatives to traditional chemical processes, driven by increasing environmental concerns and regulatory pressures, leading to a surge in demand for biocatalysts in various sectors [12][13]. - The market for biocatalysts is expected to grow as consumer preferences shift towards sustainable and bio-based products, although challenges such as catalyst stability and long development cycles remain [12].

Core Viewpoint - Guangdong Yidoli Biotechnology Co., Ltd. held an online investor meeting to discuss its mid-year performance and future strategies, focusing on product development and market expansion [1][2]. Group 1: Investor Relations Activity - The investor meeting took place on September 19, 2025, from 15:30 to 17:00 on the "Panorama Roadshow" website [2]. - Key personnel present included CEO Zhou Derong, independent director Yuan Ziqiang, CFO Huang Xiaoping, and board secretary Zhu Shanmin [2]. Group 2: Product Development and Market Strategy - The company has ceased production of Vitamin B12 due to market conditions and has made progress in animal plant extracts, completing various trials and obtaining new product certificates for red clover and stone mint extracts [2]. - In the human plant extract segment, the company developed multiple new products and optimized extraction processes, aiming for significant sales growth in overseas markets, with preparations for its German subsidiary completed [2]. Group 3: Production Capacity and Marketing - In 2024, the company produced 41,533 tons of biological enzyme preparations and sold 42,383 tons, achieving near full capacity utilization [2]. - The company is investing in new and upgraded projects across four bases to increase production capacity, while also expanding its global market presence by registering products in over 30 countries and establishing long-term partnerships with more than 2,300 quality clients [2]. Group 4: Shareholder Information and Market Management - As of September 10, 2025, the company had 20,222 shareholders [2]. - The management is focusing on core business development, research innovation, global market expansion, and efficiency improvements to achieve performance growth and high-quality development, alongside cash dividends, share buybacks, and equity incentives for market value management [2].

Production and Market Strategy - The company has halted the production of Vitamin B12 due to market reasons [2] - In 2024, the production of biological enzyme preparations reached 41,533 tons, with sales of 42,383 tons, indicating a near-saturation capacity utilization [2] - The company is focusing on expanding its global market presence, having registered products in over 30 countries and established long-term partnerships with over 2,300 clients [2] Research and Development - The company has made progress in developing new products, including plant extracts and fermentation products, while optimizing extraction processes for various plants [2] - New product certifications have been obtained for feed and feed additives, enhancing the company's product portfolio [2] Financial Performance and Shareholder Engagement - As of September 10, 2025, the number of shareholders is 20,222 [4] - The management is committed to improving company performance and achieving the goals set in the equity incentive plan over the next three years [5] - The company is actively engaging in value management through cash dividends, share buybacks, and equity incentives [6] Market Position and Challenges - The company is addressing the challenge of its stock price being close to net asset value, which is uncommon for growth stocks [5] - The management emphasizes the importance of maintaining a strong domestic market position while pursuing international expansion [5]

本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参与 本次互动交流，活动时间为 2025 年 9 月 19 日（周五）15:30-17:00。 届时公司总裁周德荣先生、独立董事袁自强先生、财务总监黄小平先生、董 事会秘书朱善敏女士将在线就公司 2025 年半年度业绩、公司治理、发展战略、 经营状况和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广 大投资者踊跃参与！ 特此公告。 广东溢多利生物科技股份有限公司 董事会 股票代码：300381 股票简称：溢多利 公告编号：2025-046 广东溢多利生物科技股份有限公司 关于参加广东辖区 2025 年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，广东溢多利生物科技股份有限公司（以 下简称"公司"）将参加由广东证监局、广东上市公司协会联合举办的"向新提 质 价值领航——2025年广东辖区投资者集体接待日暨辖区上市公司中报业绩说 明会 ...

Core Insights - The development of the silage feed additive industry in China began in the early 1980s, lagging behind developed countries in Europe and America [1] - The industry has entered a rapid growth phase since the 21st century, driven by the increasing level of intensive farming and the maturation of the silage feed industrial system [1] - The market size of the silage feed additive industry in China was approximately 21.44 billion yuan in 2020, recovering from a decline due to African swine fever in 2019 [1] - In 2023, the market size experienced a year-on-year decline of 4.93% due to factors such as adjustments in pig production capacity and low breeding efficiency [1] - The industry is expected to stabilize in 2024, with a projected market size of around 31.55 billion yuan [1] Industry Overview - Silage feed additives are designed to inhibit the growth of harmful microorganisms, reduce nutrient loss, and ensure fermentation effectiveness [7] - The industry chain includes upstream raw materials, midstream product development and production, and downstream applications in livestock farming [7] - The main types of silage feed additives used in China include fermentation promoters, fermentation inhibitors, and nutritional additives [7] Market Trends - The silage feed additive industry is expected to focus on green development, emphasizing the use of natural plant extracts and probiotics to reduce chemical residues and environmental pollution [14] - Functional innovation will be a key trend, with a focus on developing multi-functional additives that improve fermentation quality and enhance animal health [15] - The industry will pursue higher efficiency and precision through technological upgrades, aiming for optimized application and reduced costs [16] Key Companies - Major companies in the silage feed additive industry include Xinghuo Technology, Ruipu Biological, Yidoli, Tiankang Biological, and New Hope [2] - Xinghuo Technology specializes in bio-fermentation and chemical synthesis, with a focus on food and feed additives [12] - Yidoli is a biotechnology company engaged in the research and production of biological enzymes and plant extracts for animal nutrition [13]

股票代码：300381 股票简称：溢多利 公告编号：2025-045 广东溢多利生物科技股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示 1、本次股东大会召开期间没有增加、否决或变更提案； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 1、会议召开时间： 现场会议时间：2025 年 9 月 12 日（星期五）下午 2:30 网络会议时间：2025 年 9 月 12 日。其中，通过深圳证券交易所交易系统 进行网络投票的时间为 2025 年 9 月 12 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网系统投票的具体时间为 2025 年 9 月 12 日 9:15 至 15:00 的任意时间。 2、现场会议召开地点：珠海市南屏科技园屏北一路 8 号公司会议中心。 3、会议召开和投票方式：现场投票与网络投票相结合的方式 （1）现场投票：包括本人出席或通过填写授权委托书授权他人出席。 （2）网络投票：公司将通过深圳证券交易所交易系统和互联网投票系统 向 ...

北京德恒（深圳）律师事务所 关于广东溢多利生物科技股份有限公司 2025 年第二次临时股东大会的 法律意见 深圳市福田区金田路 4018 号安联大厦 B 座 11 层 电话：0755-88286488 传真：0755-88286499 邮编：518026 ————————————————————————————— ————————————————————————————— 北京德恒（深圳）律师事务所 关于广东溢多利生物科技股份有限公司 2025 年第二次临时股东大会的法律意见 北京德恒（深圳）律师事务所 关于广东溢多利生物科技股份有限公司 2025 年第二次临时股东大会的 法律意见 德恒 06G20240488-0003 号 （四）公司于 2025 年 8 月 28 日在巨潮资讯网（http://www.cninfo.com.cn）公布 的《关于召开 2025 年第二次临时股东大会的通知》（以下简称"《股东大会通知》"）； （五）公司本次股东大会现场参会股东、股东代理人到会登记记录及凭证资料、 授权委托书； 致：广东溢多利生物科技股份有限公司 北京德恒（深圳）律师事务所 关于广东溢多利生物科技股份有限公司 2 ...

Group 1 - The company announced it will use no more than 30 million RMB for securities investment, addressing investor concerns about the involvement of board members and their experience in securities investment [1] - The company clarified that this securities investment will utilize idle self-owned funds and will not affect the normal operations of the company and its subsidiaries [1] - The company plans to prioritize investments in new stock placements or subscriptions while aiming to minimize operational risks [1]

Financial Performance - Company reported a total revenue of 415 million yuan for the first half of 2025, an increase of 4.48% year-on-year [1] - Net profit attributable to shareholders was 13.997 million yuan, a significant decrease of 66.5% compared to the previous year [1] - In Q2 2025, total revenue reached 213 million yuan, up 7.17% year-on-year, while net profit was 9.1264 million yuan, down 58.8% [1] Profitability Metrics - Gross margin stood at 46.06%, a decline of 1.54% year-on-year [1] - Net margin was 3.51%, reflecting a decrease of 66.74% compared to the previous year [1] - Total expenses (selling, administrative, and financial) amounted to 121 million yuan, accounting for 29.11% of revenue, an increase of 5.71% year-on-year [1] Shareholder Metrics - Earnings per share (EPS) was 0.03 yuan, down 66.59% year-on-year [1] - Book value per share was 5.26 yuan, a decrease of 1.4% compared to the previous year [1] - Operating cash flow per share was 0.0 yuan, a drastic decline of 97.34% year-on-year [1] Capital Efficiency - The company's return on invested capital (ROIC) was 0.93% last year, indicating weak capital returns [3] - Historical median ROIC over the past decade was 5.47%, with the worst year being 2021 at -1.33% [3] - The company has reported two years of losses since its IPO, suggesting a fragile business model [3] Accounts Receivable - The accounts receivable to profit ratio reached 709.12%, indicating potential issues with cash flow management [3]